Profound Medical Corp. (NASDAQ:PROF), announced entering into a co-education agreement with Telix Pharmaceuticals Limited (NASDAQ:TLX), a commercial-stage global radiopharmaceutical company.
The agreement establishes a framework through which the companies intend to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix’s advanced prostate-specific membrane antigen targeting PET molecular imaging technologies, Gozellix® and Illuccix®1, and Profound’s MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO® platform across the prostate care continuum.
Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, as well as the development of educational content, clinical case studies and best-practice materials.
The collaboration is intended to increase physician awareness of PSMA-informed treatment pathways, support appropriate patient selection and treatment planning, and expand access to the TULSA Procedure™.
Profound’s broader strategic objective is to explore opportunities that could expand the clinical utility and adoption of TULSA-PRO.
PSMA-PET imaging may help physicians determine whether certain patients with higher-risk disease remain appropriate candidates for the TULSA Procedure by identifying distant metastases or disease beyond the prostate that may not otherwise be readily detected.
Profound believes this additional diagnostic information could enable more precise patient stratification and potentially broaden the population considered for the TULSA Procedure.
PROF gained 4.5 cents to $6.96, while those for TLX acquired 13 cents, or 1.1%, to $11.14.
Related Stories
